A randomized, placebo‐controlled clinical trial of hydrogen/oxygen inhalation for non‐alcoholic fatty liver disease

Non‐alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease worldwide with increasing incidence consistent with obesity, type 2 diabetes and cardiovascular diseases. No approved medication was currently available for NAFLD treatment. Molecular hydrogen (H(2)), an anti‐oxidativ...

Descripción completa

Detalles Bibliográficos
Autores principales: Tao, Geru, Zhang, Guangjie, Chen, Wei, Yang, Chao, Xue, Yazhuo, Song, Guohua, Qin, Shucun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279585/
https://www.ncbi.nlm.nih.gov/pubmed/35734974
http://dx.doi.org/10.1111/jcmm.17456

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9279585/
https://www.ncbi.nlm.nih.gov/pubmed/35734974
http://dx.doi.org/10.1111/jcmm.17456

Ejemplares similares